Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 1/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | CCND3 | P30281 | 1/20 | 0.65 |
| ▸ | CDK9 | P50750 | 1/20 | 0.65 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.65 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.64 |
| ▸ | BRD4 | O60885 | 3/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.63 |
| ▸ | IGF1R | P08069 | 2/20 | 0.63 |
| ▸ | INSR | P06213 | 1/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.63 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.61 |
| ▸ | SYK | P43405 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11915885 | 0.92 | PKMYT1 (0.74) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL11919317 | 0.89 | PDGFRB (0.63) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL11916604 | 0.89 | CCNK (0.66) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL22515459 | 0.87 | INSR (0.60) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL11919190 | 0.87 | ALK (0.73) | CDK2PTK2IGF1RINSRPTK2B | |
| SCHEMBL11915907 | 0.86 | FGFR1 (0.63) | BRD4IGF1REGFRALKSYK | |
| SCHEMBL11916385 | 0.86 | FGFR1 (0.63) | BRD4IGF1REGFRALKSYK | |
| SCHEMBL21709636 | 0.83 | BRD4 (0.56) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL19203865 | 0.83 | CCNK (0.67) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL11916403 | 0.82 | JAK2 (0.63) | CCNKCCNA2CDK2CCND3CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CCNK 393/4885CCNA2 801/4885CDK2 59/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CCNK 376/4885CCNA2 801/4885CDK2 51/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | CCNK 404/4885CCNA2 871/4885CDK2 105/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | CCNK 376/4885CCNA2 801/4885CDK2 51/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CCNK 402/4885CCNA2 873/4885CDK2 90/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CCNK 402/4885CCNA2 873/4885CDK2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.